D. L. Wickerham

3.6k total citations · 1 hit paper
23 papers, 2.6k citations indexed

About

D. L. Wickerham is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, D. L. Wickerham has authored 23 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Cancer Research and 9 papers in Genetics. Recurrent topics in D. L. Wickerham's work include Breast Cancer Treatment Studies (13 papers), Estrogen and related hormone effects (8 papers) and Cancer Risks and Factors (5 papers). D. L. Wickerham is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), Estrogen and related hormone effects (8 papers) and Cancer Risks and Factors (5 papers). D. L. Wickerham collaborates with scholars based in United States, Canada and Japan. D. L. Wickerham's co-authors include Norman Wolmark, Edwin R. Fisher, Bernard Fisher, Carol Redmond, Howard E. Rockette, Richard G. Margolese, Judy Jones, S Legault-Poisson, B. Fisher and Stewart Anderson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

D. L. Wickerham

23 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Postoperative Adjuvant Chemotherapy or Radiation Therapy for Rectal Cancer: Results From NSABP Protocol R-011

1988 754 citations B. Fisher, Norman Wolmark et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. L. Wickerham United States	13	1.8k	1.1k	913	748	434	23	2.6k
Barry C. Lembersky United States	31	2.5k 1.3×	1.1k 1.0×	663 0.7×	555 0.7×	764 1.8×	82	3.3k
P. Fargeot France	30	1.7k 0.9×	899 0.8×	564 0.6×	326 0.4×	575 1.3×	87	2.7k
Anna Rossi Italy	19	1.4k 0.8×	1.1k 1.0×	399 0.4×	467 0.6×	410 0.9×	46	2.4k
Linda D. Bosserman United States	24	1.8k 1.0×	1.1k 1.0×	711 0.8×	740 1.0×	513 1.2×	89	3.3k
Giuseppe Canavese Italy	26	650 0.4×	1.0k 0.9×	612 0.7×	787 1.1×	212 0.5×	76	1.8k
Karin Zedeler Denmark	22	1.5k 0.8×	2.6k 2.4×	1.1k 1.2×	1.5k 2.0×	444 1.0×	34	3.5k
Julia Kurtz Switzerland	15	709 0.4×	1.1k 1.0×	574 0.6×	720 1.0×	177 0.4×	34	1.7k
Pinuccia Valagussa Italy	10	1.2k 0.7×	1.0k 1.0×	195 0.2×	439 0.6×	256 0.6×	11	1.8k
Herman Høst Norway	21	1.1k 0.6×	1.3k 1.2×	469 0.5×	686 0.9×	532 1.2×	66	2.5k
Susanne Taucher Austria	23	1.1k 0.6×	954 0.9×	221 0.2×	456 0.6×	180 0.4×	45	1.7k

Countries citing papers authored by D. L. Wickerham

Since Specialization

Citations

This map shows the geographic impact of D. L. Wickerham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. L. Wickerham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. L. Wickerham more than expected).

Fields of papers citing papers by D. L. Wickerham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. L. Wickerham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. L. Wickerham. The network helps show where D. L. Wickerham may publish in the future.

Co-authorship network of co-authors of D. L. Wickerham

This figure shows the co-authorship network connecting the top 25 collaborators of D. L. Wickerham. A scholar is included among the top collaborators of D. L. Wickerham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. L. Wickerham. D. L. Wickerham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mamounas, Eleftherios P., Hanna Bandos, Barry C. Lembersky, et al.. (2020). Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). Cancer Research. 80(4_Supplement). GS4–1. 12 indexed citations

Mamounas, EP, Hanna Bandos, BC Lembersky, et al.. (2017). Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Cancer Research. 77(4_Supplement). S1–5. 37 indexed citations

Mamounas, EP, Grace H. Tang, Seungmok Paik, et al.. (2012). Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28. Cancer Research. 72(24_Supplement). S1–10. 19 indexed citations

Wickerham, D. L., et al.. (2011). Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT).. Journal of Clinical Oncology. 29(15_suppl). 1505–1505. 4 indexed citations

Vogel, Victor G., Joseph P. Costantino, D. L. Wickerham, et al.. (2010). Carcinoma In Situ Outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. JNCI Monographs. 2010(41). 181–186. 14 indexed citations

Ingle, JN, D. L. Wickerham, Taisei Mushiroda, et al.. (2010). Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration. Cancer Research. 70(24_Supplement). PD05–2. 4 indexed citations

Yothers, Greg, et al.. (2008). Neurotoxicity (NT) in colon cancer (CC) survivors from NSABP Protocol C-07 comparing 5-FU + leucovorin (FULV) with the same regimen + oxaliplatin (FLOX): Preliminary results from NSABP Protocol LTS-01. Journal of Clinical Oncology. 26(15_suppl). 9575–9575. 3 indexed citations

McCaskill‐Stevens, Worta, John Wilson, John Bryant, et al.. (2004). Contralateral Breast Cancer and Thromboembolic Events in African American Women Treated With Tamoxifen. JNCI Journal of the National Cancer Institute. 96(23). 1762–1769. 20 indexed citations

Tan-Chiu, Elizabeth, Jiping Wang, Joseph P. Costantino, et al.. (2003). Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer. JNCI Journal of the National Cancer Institute. 95(4). 302–307. 61 indexed citations

10.

Wickerham, D. L.. (2002). Tamoxifen versus raloxifene in the prevention of breast cancer. European Journal of Cancer. 38. 20–21. 4 indexed citations

11.

Wickerham, D. L.. (2001). Breast cancer chemoprevention: Current status and future directions. Seminars in Oncology. 28(3). 253–259. 12 indexed citations

12.

Smith, Rebecca L., D. L. Wickerham, Harry S. Wieand, Linda H. Colangelo, & E.P. Mamounas. (1999). UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.. PubMed. 13(7 Suppl 3). 44–7. 11 indexed citations

13.

Wolmark, Norman, Howard E. Rockette, Eleftherios P. Mamounas, et al.. (1999). Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project C-04. Journal of Clinical Oncology. 17(11). 3553–3559. 344 indexed citations

14.

Fisher, Bernard, James J. Dignam, Birol Emir, et al.. (1997). Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer. JNCI Journal of the National Cancer Institute. 89(22). 1673–1682. 366 indexed citations

15.

Mamounas, E.P., et al.. (1997). Future directions in the adjuvant treatment of colon cancer.. PubMed. 11(9 Suppl 10). 44–7. 7 indexed citations

16.

Fisher, Bernard, Arthur P. DeCillis, D. L. Wickerham, & Walter M. Cronin. (1994). The National Surgical Adjuvant Breast and Bowel Project. Oncology Issues. 9(4). 17–18. 1 indexed citations

17.

Fisher, Bernard, D. L. Wickerham, Melvin Deutsch, et al.. (1992). Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings.. PubMed. 8(3). 153–60. 85 indexed citations

18.

Fisher, Bernard, Stewart Anderson, Edwin R. Fisher, et al.. (1991). Significance of ipsilateral breast tumour recurrence after lumpectomy. The Lancet. 338(8763). 327–331. 423 indexed citations

19.

Fisher, B., Carol Redmond, N V Dimitrov, et al.. (1989). A Randomized Clinical Trial Evaluating Sequential Methotrexate and Fluorouracil in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Negative Tumors. New England Journal of Medicine. 320(8). 473–478. 305 indexed citations

20.

Fisher, B., Norman Wolmark, Howard E. Rockette, et al.. (1988). Postoperative Adjuvant Chemotherapy or Radiation Therapy for Rectal Cancer: Results From NSABP Protocol R-011. JNCI Journal of the National Cancer Institute. 80(1). 21–29. 754 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact